THOUSAND OAKS, Calif.,
May 14, 2015 /PRNewswire/
-- Amgen (NASDAQ: AMGN) today announced voting results from
the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately
89 percent of outstanding shares were represented at the
meeting.
The director nominees David
Baltimore, Frank J. Biondi,
Jr., Robert A. Bradway,
François de Carbonnel, Vance D.
Coffman, Robert A. Eckert,
Greg C. Garland, Rebecca M. Henderson, Frank C. Herringer, Tyler Jacks, Judith C.
Pelham, Ronald D. Sugar, and
R. Sanders Williams were each
re-elected to Amgen's Board of Directors. Each director received at
least 92 percent of the votes cast "For." With the re-election of
all of the director nominees, Amgen currently has 13 directors.
With approximately 99 percent of the votes cast "For,"
stockholders ratified Ernst & Young LLP as Amgen's independent
registered public accountants for the year ending Dec. 31, 2015.
Stockholders approved, on an advisory basis, the named executive
officer compensation, commonly known as "Say on Pay." The
non-binding proposal gives stockholders the opportunity to endorse
or not endorse Amgen's executive pay programs and policies. Say on
Pay received approximately 97 percent of the votes cast "For" the
proposal.
The stockholder proposal regarding vote tabulation did not pass,
receiving approximately 6 percent of the votes cast "For" the
proposal.
About Amgen
Amgen is committed to unlocking the
potential of biology for patients suffering from serious illnesses
by discovering, developing, manufacturing and delivering innovative
human therapeutics. This approach begins by using tools like
advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its biologics manufacturing expertise to strive for solutions that
improve health outcomes and dramatically improve people's lives. A
biotechnology pioneer since 1980, Amgen has grown to be one of the
world's leading independent biotechnology companies, has reached
millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.
Forward-Looking Statements
This news release contains
forward-looking statements that involve significant risks and
uncertainties, including those discussed below and others that can
be found in our Form 10-K for the year ended Dec. 31, 2014, and in any subsequent periodic
reports on Form 10-Q and Form 8-K. Amgen is providing this
information as of the date of this news release and does not
undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future
events or otherwise.
No forward-looking statement can be guaranteed and actual
results may differ materially from those we project. The
Company's results may be affected by our ability to successfully
market both new and existing products domestically and
internationally, clinical and regulatory developments (domestic or
foreign) involving current and future products, sales growth of
recently launched products, competition from other products
(domestic or foreign) and difficulties or delays in manufacturing
our products. In addition, sales of our products are affected by
reimbursement policies imposed by third-party payers, including
governments, private insurance plans and managed care providers and
may be affected by regulatory, clinical and guideline developments
and domestic and international trends toward managed care and
healthcare cost containment as well as U.S. legislation affecting
pharmaceutical pricing and reimbursement. Government and others'
regulations and reimbursement policies may affect the development,
usage and pricing of our products. Furthermore, our research,
testing, pricing, marketing and other operations are subject to
extensive regulation by domestic and foreign government regulatory
authorities. We or others could identify safety, side effects or
manufacturing problems with our products after they are on the
market. Our business may be impacted by government investigations,
litigation and product liability claims. If we fail to meet
the compliance obligations in the corporate integrity agreement
between us and the U.S. government, we could become subject to
significant sanctions. Further, while we routinely obtain patents
for our products and technology, the protection offered by our
patents and patent applications may be challenged, invalidated or
circumvented by our competitors. We depend on third parties
for a significant portion of our manufacturing capacity for the
supply of certain of our current and future products and limits on
supply may constrain sales of certain of our current products and
product candidate development. In addition, we compete with
other companies with respect to some of our marketed products as
well as for the discovery and development of new products.
Discovery or identification of new product candidates cannot be
guaranteed and movement from concept to product is uncertain;
consequently, there can be no guarantee that any particular product
candidate will be successful and become a commercial product.
Further, some raw materials, medical devices and component parts
for our products are supplied by sole third-party suppliers. Our
efforts to integrate the operations of companies we have acquired
may not be successful. We may experience difficulties, delays
or unexpected costs and not achieve anticipated benefits and
savings from our recently announced restructuring plan. Our
business performance could affect or limit the ability of the Amgen
Inc. Board of Directors to declare a dividend or our ability to pay
a dividend or repurchase our common stock.
CONTACT: Amgen, Thousand
Oaks
Cuyler Mayer, 805-447-6332
(media)
Arvind Sood, 805-447-1060
(investors)
Logo -
http://photos.prnewswire.com/prnh/20081015/AMGENLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amgen-announces-voting-results-of-annual-meeting-of-stockholders-300083910.html
SOURCE Amgen